Overview

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a open Label, balanced, randomized, single dose, two-treatment, two-sequence, two-period, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in healthy, adult human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Etodolac